NIH-funded research NIH-funded research

Evaluating immune modulator drugs for COVID-19 treatment in hospitalized adults

Official title: ACTIV-1 TIME-LIMITED BIOSPECIMEN STORAGE AND RELATED SERVICES (COVID-19), OPTION QUANTITY 1 STATISTICAL SUPPORT, OPTION QUANTITY 2 BIOSPECIMEN ANALYSI

Funded at Technical Resources International, INC. · NIH-10722555 · Data updated 2026-11-12

This study is looking at how well three different immune system drugs work for treating COVID-19 by collecting and analyzing samples from adults in the hospital, and your participation could help us understand their safety and benefits for patients like you.

More COVID-19 research and trials

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionTechnical Resources International, INC.
NIH-funded
Lab location1 site (Bethesda, United States)
Project startSeptember 22, 2022
Project endSeptember 21, 2025
Funding year2022
Award (this year)$2,701,936
NIH project number75N95022C00032-0-9999-1
Project IDNIH-10722555 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are hospitalized adults aged 21 and older who are receiving treatment for COVID-19.

Less likely to help

Patients who are not hospitalized or those under 21 years old may not benefit from this research.

What this research studies

This research focuses on the long-term storage, distribution, and analysis of biospecimens collected from hospitalized adults participating in a clinical trial. The trial aims to assess the safety and effectiveness of three different immune modulator drugs in treating COVID-19. By analyzing these biospecimens, researchers hope to gain insights into how these drugs work and their potential benefits for patients. Participation in this research may involve providing biological samples, which will be carefully stored and analyzed over time.

Why it matters

Potential benefit: If successful, this research could lead to improved treatment options for hospitalized adults suffering from COVID-19.

How similar studies have gone: Previous research has shown promise in using immune modulators for treating COVID-19, indicating that this approach may yield valuable insights.

Where this research is happening

  • Technical Resources International, INC.
    Bethesda, United States
    Active

Researchers

  • Principal investigator: Butler, Sandra — Technical Resources International, INC.
  • Study coordinator: Butler, Sandra

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.